因危重疾病需要 ICU 护理的血液系统恶性肿瘤患者的治疗结果并不理想，并且是该人群中未满足的主要需求。我们提供的数据来自专门的血液肿瘤学环境，其中包括 63 名因危重疾病并伴有器官功能障碍而入住 ICU 的中位年龄为 60 岁的患者。最常见的潜在诊断是多发性骨髓瘤（30%），其次是急性髓系白血病（25%）。 90.7%的患者在入住ICU前已开始化疗。 ICU 护理最常见的适应症是呼吸衰竭（36.5%）和休克（17.5%）患者。 44 名 (69%) 患者存在败血症的证据。转入 ICU 后，32 名患者 (50%) 需要正性肌力支持，18 名患者 (28%) 需要有创机械通气。平均入住 ICU 5 天后，43.1% 的患者死亡，最常见的原因是多器官功能障碍。涉及两个以上主要器官 (p = .001)、潜在 AML (p = .001)、需要机械通气 (p = .001) 和高正性肌力药物使用 (p = .004) 时，死亡风险较高。中性粒细胞减少症与死亡率无关。我们的研究表明短期死亡率很高，并定义了可用于预测患者和建立护理目标的预后因素。在线版本包含补充材料，请访问 10.1007/s12288-024-01757-3。© 作者，获得印度血液学和输血学会 2024 的独家许可。Springer Nature 或其许可方（例如协会或其他合作伙伴）根据与作者或其他权利持有人的出版协议拥有本文的专有权；作者对本文已接受的手稿版本的自行存档仅受此类出版协议和适用法律的条款的约束。

Outcomes of patients with hematologic malignancies requiring ICU care for critical illness are suboptimal and represent a major unmet need in this population. We present data from a dedicated haematology oncology setting including 63 patients with a median age of 60 years admitted to the ICU for critical illness with organ dysfunction. The most common underlying diagnosis was multiple myeloma (30%) followed by acute myeloid leukemia (25%). Chemotherapy had been initiated for 90.7% patients before ICU admission. The most common indication for ICU care was respiratory failure (36.5%) and shock (17.5%) patients. Evidence of sepsis was present in 44 (69%) patients. After shifting to ICU, 32 (50%) patients required inotropic support and 18 (28%) required invasive mechanical ventilation. After a median of 5 days of ICU stay, 43.1% patients had died, most commonly due to multiorgan dysfunction. Risk of mortality was higher with involvement of more than two major organs (p = .001), underlying AML (p = .001), need for mechanical ventilation (p = .001) and high inotrope usage (p = .004). Neutropenia was not associated with mortality. Our study indicates high rates of short term mortality and defines prognostic factors which can be used to prognosticate patients and establish goals of care.The online version contains supplementary material available at 10.1007/s12288-024-01757-3.© The Author(s), under exclusive licence to Indian Society of Hematology and Blood Transfusion 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.